Aldossary, Ahmad Mohammad;
(2018)
Correction of the ΔF508 mutation in the CFTR Gene by CRISPR/Cas9 system.
Doctoral thesis (Ph.D), UCL (University College London).
Preview |
Text
Ahmad PhD Thesis.pdf Download (14MB) | Preview |
Abstract
Cystic Fibrosis (CF) is one of the most common autosomal recessive genetic diseases. It is caused by mutations in the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR). CF causes chronic lung disease including thickened mucus, bacterial infection and inflammation, with a progressive loss of pulmonary function and, ultimately, death. Several clinical trials have been performed to date assessing the potential of gene therapy to limit the progression of CF lung disease. However, a clinically relevant treatment has yet to emerge. The major challenges in gene therapy for CF relate to the limited levels of gene transfer achieved in the lung airway epithelium, and the persistence of transgene expression. Here we are investigating the potential of genome editing to develop a genetic therapy for CF using the CRISPR/Cas system that allows for gene-specific, targeted correction of disease-related mutations to be introduced at the chromosomal level. In particular, we aim to investigate the therapeutic potential for ΔF508 mutation cystic fibrosis, which is the most common CF mutation and affects more than 70% of patients. Initially, multiple guide RNAs were screened for double strand break (DSB), targeting the CFTR gene close to the ΔF508 mutation on the CFBE41o- cell line. The efficient gRNAs were used for the mutation correcting through homology directed repair (HDR) after which the cells were cloned. The correction was confirmed at the molecular level, followed by restoring the electrophysiology function and the mRNA expression. This work was also extended to correct the mutation on primary CFBE cells where the editing was optimized with Cas9 mRNA/gRNA and ribonucleoprotein (RNP) was delivered by Receptor-Targeted Nanocomplex (RTN). To improve the editing efficiency, the homology-independent targeted integration (HITI) strategy as an alternative for HDR, was used to investigate the CFTR exon 10 in CFBE41o- being replaced with wildtype exon. The gene editing in vivo was explored successfully in a mice reporter model to restore tdTomato expression by paired gRNAs excision the stop cassette where targeting nanocomplex was used as a safe and non-immunogenic delivery method.
Type: | Thesis (Doctoral) |
---|---|
Qualification: | Ph.D |
Title: | Correction of the ΔF508 mutation in the CFTR Gene by CRISPR/Cas9 system |
Event: | UCL(University college London |
Open access status: | An open access version is available from UCL Discovery |
Language: | English |
Additional information: | Copyright © The Author 2018. Original content in this thesis is licensed under the terms of the Creative Commons Attribution 4.0 International (CC BY 4.0) Licence (https://creativecommons.org/licenses/by/4.0/). Any third-party copyright material present remains the property of its respective owner(s) and is licensed under its existing terms. Access may initially be restricted at the author’s request. |
UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > UCL GOS Institute of Child Health UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > UCL GOS Institute of Child Health > Genetics and Genomic Medicine Dept |
URI: | https://discovery.ucl.ac.uk/id/eprint/10064316 |
Archive Staff Only
View Item |